Direkt zum Inhalt
Merck
  • The use of erythromycin and colistin-loaded cement in total knee arthroplasty does not reduce the incidence of infection: a prospective randomized study in 3000 knees.

The use of erythromycin and colistin-loaded cement in total knee arthroplasty does not reduce the incidence of infection: a prospective randomized study in 3000 knees.

The Journal of bone and joint surgery. American volume (2013-05-03)
Pedro Hinarejos, Pau Guirro, Joan Leal, Ferran Montserrat, Xavier Pelfort, M L Sorli, J P Horcajada, Lluis Puig
ZUSAMMENFASSUNG

The use of antibiotic-loaded cement is believed to prevent infection in primary total knee arthroplasty, but there is a lack of randomized studies to support this concept. The aim of this study was to evaluate the use of an antibiotic-loaded cement to reduce the infection rate in primary total knee arthroplasty. This is a prospective randomized study with 2948 cemented total knee arthroplasties, in which bone cement without antibiotic was used in 1465 knees (the control group) and a bone cement loaded with erythromycin and colistin was used in 1483 knees (the study group). All patients received the same systemic prophylactic antibiotics. The patients were followed for a minimum of twelve months. The rate of infection was analyzed according to the criteria of the Centers for Disease Control and Prevention. The rate of deep infection (1.4% in the control group and 1.35% in the study group; p = 0.96) and the rate of superficial infection (1.2% and 1.8%, respectively; p = 0.53) were similar in both groups. The factors related to a higher rate of deep infection in a multivariate analysis were male sex and an operating time of >125 minutes. The use of erythromycin and colistin-loaded bone cement in total knee arthroplasty did not lead to a decrease in the rate of infection when systemic prophylactic antibiotics were used, a finding that suggests that the use of antibiotic-loaded bone cement would not be indicated in the general population. Further research is needed to assess whether its use is recommended for patients with a higher risk of infection.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin-Standard -Lösung, 1 mg/mL in H2O
Supelco
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.